HLA-B*57:01
Test Mnemonic
B5701
CPT Codes
- 81381 - QTY (1)
Aliases
- Abacavir Hypersensitivity
- HLA-B*57:01 Genotyping
Performing Laboratory
Allogen Laboratories
FDA Category
Laboratory Developed Test
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 5 mL | Whole blood | EDTA (Lavender) | Ambient |
Alternate Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 7 mL | Whole blood | ACD A or B (Yellow) | Ambient |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | 1 week |
| Refrigerated | 1 week |
| Frozen | Unacceptable |
Days Performed
Mon - Fri
Turnaround Time
6 - 8 days
Methodology
| Name | Description |
|---|---|
| Polymerase Chain Reaction (PCR) | |
| Polymerase Chain reaction(PCR)/Sequence Specific Oligo Probes(SSO) | |
| Sequence based typing, PCR |
Reference Range
Special Info
Informed consent is required for patients residing in New York state.Transfusions will interfere with testing for up to 4 - 6 weeks. Allogenic bone marrow or stem cell transplants will interfere with testing.
Clinical Info
The presence of HLA-B*57:01 allele is associated with significantly increased risk for the development of Abacavir hypersensitivity reaction (HSR) compared to the general population. Treatment with Abacavir in subjects positive for HLA-B*57:01 should be avoided. A negative result does not preclude the development of an allergic response to Abacavir and cannot substitute for clinical vigilance whenever Abacavir therapy is administered. Should Abacavir HSR develop, therapy should be discontinued immediately and permanently.
Clinical Reference
Positive/Negative